Overview

HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors

Status:
Recruiting
Trial end date:
2025-04-13
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to evaluate the feasibility and safety of HPV-T in HPV 16 positive recurrent or metastatic solid tumor patients.
Phase:
Phase 1
Details
Lead Sponsor:
BGI, China
Collaborator:
Wuhan Union Hospital, China
Treatments:
Interleukin-2